Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-25-047844
Filing Date
2025-05-13
Accepted
2025-05-13 16:20:22
Documents
15
Period of Report
2025-04-15
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2514727d1_8ka.htm   iXBRL 8-K/A 31223
2 EXHIBIT 99.6 tm2514727d1_ex99-6.htm EX-99.6 411863
3 EXHIBIT 99.7 tm2514727d1_ex99-7.htm EX-99.7 184860
  Complete submission text file 0001104659-25-047844.txt   885412

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tvrd-20250415.xsd EX-101.SCH 3044
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvrd-20250415_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvrd-20250415_pre.xml EX-101.PRE 22378
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2514727d1_8ka_htm.xml XML 3695
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36279 | Film No.: 25940437
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)